Krönika: Can regulators keep up with innovation?

New technology has increased the understanding of disease mechanisms and enabled approval of products targeting small but specific patient populations; sometime...

Nordic Regulatory experts: Improving biotech chances of Succ

Why is it that so many biotech companies fail? And what are the tools needed to change that fact?

Oasmias villkor klara

Två kronor per aktier – så ser villkoren ut för den tidigare aviserade emission på cirka 400 miljoner som läkemedelsutvecklaren Oasmia förbereder. Börskursen fa...

Marie Gårdmark: Finally, it’s time for a revision of the EU pharma legislation

A challenge for the EU Commission is to deliver a new framework that will also take care of another “pillar” of the pharmaceutical strategy, namely, to ensure t...

Krönika: Collaboration across borders

Helena Strigård: The rise of the community

Sweden Bio´s CEO is looking back at the last decade of development in the industry. Something has shifted in the interdependence between small and larger companies.

Sweden and Denmark – this is how they choose their strategies

Scandinavia’s two major powers in pharmaceutical research have developed strategies for growth in life science, and both countries aim to become world leaders.

Björn Arvidsson: Let's build on the positive momentum

Progress needs narratives and heroes, and more than ever, going into the new year feels like an opportunity for a fresh start.

Upcoming event: New updates on drugs

At Medicon Valley Alliance venues in Copenhagen/Örestad April 1 2020 the meeting New updates in Drug Formulation & Bioavailability takes place for the for the eighth time.

Pharma-on-Demand

Make or buy? That is the question that the pharma world has been asking more and more in the last couple of decades. Pernille Hemmingsen is moderator at Pharma ...

Meet the governmental life science office

More clinical trials, promotion for digitisation and interoperability together with increased use of data generated by both healthcare and individuals. The duti...

The best wealth is Health

We are living in a world where wealth more and more is measured in being able to do the things you like and enjoy in life. As the wealth increases in terms of e...

Samuel Lagercrantz: Collaboration and joint efforts are the key to success

Although many questions about Covid-19 remain unanswered, the development of drugs and vaccines has been incredibly rapid, writes Samuel Lagercrantz, Life Scien...

Atheras studie av hjärtsvikt igång

Den första patienten har behandlats i studien med en ny terapeutisk antikropp från Athera. Studien genomförs på 11 sjukhus och inkluderar patienter med akut hjä...

Medicpen förlorar upphandling

”Vi kämpar på med målet att leda förändringen av medicinhanteringssystemen”

Anna Törner: You won’t find this many Concorde projects anywhere else

"Suddenly Concorde projects seem reasonable in life science because it´s about life and death", writes Anna Törner in a column.

Opinion: Where do all the cool Swedish life science companies go?

It’s puzzling why Swedish life science companies hardly get a mention alongside Spotify, Skype, Klarna, King, iZettle, and other cool, innovative and successful...

Technia samlar life science-branschen till nytt digitalt event

Den 10 september är datumet som gäller för alla som är intresserade av den fortsatta digitaliseringen för hållbar innovation och produktutveckling inom life science.

An industry emerging from crisis

"Scanlab is normally indicative of the status of investment incentives in the laboratory industry "

Ny metod förutser lovande läkemedel

Enligt en ny studie kan forskningsbolaget Attanas teknik förbättra lyckandegraden för kliniska studier.

Marie Gårdmark: Big data evidence generation drives change in the EU regulatory system

Rapid developments in technology have led to the possibility for the generation and analysis of vast volumes of data. Will the availability of big data lead to ...

Så blir villkoren i Karo Pharmas emission

Nu har styrelsen fastställt villkoren i bolagets emission med företrädesrätt för aktieägarna.

Addvise i miljonavtal

Två dotterbolag till Addvise tecknar nytt distributionsavtal med libanesiska Alpha Pro.

Hon skrev bästa avhandlingen

”En doktorsavhandling av hög kvalitet som uppvisar en utmärkt förmåga att kommunicera vetenskap och resultat.” Så löd motiveringen när Rosenön Award delades ut.